In today's ACT Brief, we examine Thermo Fisher's acquisition of Clario to expand clinical trial data infrastructure, how ...

In successful clinical trials of drugs for inflammatory bowel disease (IBD), patients who received a placebo were at significantly higher risk for potential harms, according to two systematic reviews.

Symptoms of inflammatory bowel disease (IBD) range from diarrhea and abdominal pain to nausea, fever, loss of appetite, fatigue and, at times, rectal bleeding. No single test can confirm IBD, which ...

The somatic genomics approach analyses naturally accumulated genetic mutations within individual patient tissue.

Notable news about inflammatory bowel disease (IBD) in 2024 included a study evaluating loss of response to tumor necrosis factor (TNF) blockers, new FDA approvals, problems with placebos, and ...

Poster Presentation at the 2026 Crohn's & Colitis Congress® Showcases Use of Causal Machine Learning and IBD Plexus® to Optimize Trial Execution BOSTON, Jan. 22, 2026 /PRNewswire/ -- PhaseV, a leader ...

Two reviews of recent trials for drugs used to treat inflammatory bowel disease found that patients who received a placebo were at “significantly higher risk” for potential harms, MedPage Today ...

REHOVOT, ISRAEL, May 28, 2025 /EINPresswire.com/ -- PhotoPill Medical, a leader in innovative therapeutic solutions for gastrointestinal diseases, announced today the ...

(BPT) – Living with inflammatory bowel disease (IBD), such as Crohn’s disease and ulcerative colitis (UC), can be extremely frustrating to people living with the conditions and significantly affect ...

Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn’s disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 ...